Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- JT to Withdraw from OTC Business
February 19, 2001
- REGULATORY NEWS IN BRIEF -2-
February 19, 2001
- PAL Violations Found in 96 Pharmacies in 3 Years in Osaka
February 19, 2001
- Industry FTC to Ban Financial Aid for Hospitals' Social Events
February 19, 2001
- Hospitals' Income per Inpatient Down since April 2000: Survey
February 19, 2001
- Households Spent \10,865 Per Month for Healthcare in 2000
February 19, 2001
- Sales of Kampo Medicines Outdo Forecasts: Tsumura
February 19, 2001
- Number of Patients Continues to Decrease at Clinics, Dental Offices: Hodanren Survey
February 19, 2001
- Nursing Care Insurance Boosts Market for Welfare Appliances
February 19, 2001
- GSK Appeals to Tokyo High Court in Aciclovir Patent Dispute
February 19, 2001
- Merger of Medical, Nursing Care Insurance Programs Proposed: JMA Symposium
February 19, 2001
- About Half of Hospitals Reuse Single Use Devices
February 19, 2001
- BUSINESS NEWS IN BRIEF -1-
February 19, 2001
- Nat'l Univ Hospitals Directors Council to Propose One Record per Patient
February 19, 2001
- Hitachi Medical Transfers Nursing Care Business to Group Company
February 19, 2001
- BUSINESS NEWS IN BRIEF -2-
February 19, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 19, 2001
- Boston Scientific Ties Up with Islaeri, Canadian Firms in Cardiac Electrophysiology
February 19, 2001
- PMSB to Draft Criteria for Disclosure of Information
February 19, 2001
- Takara Shuzo Ties Up with GenCom for Genomic Analysis of ES Cells
February 19, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…